𝔖 Bobbio Scriptorium
✦   LIBER   ✦

ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells

✍ Scribed by Krig, S R; Miller, J K; Frietze, S; Beckett, L A; Neve, R M; Farnham, P J; Yaswen, P I; Sweeney, C A

Book ID
109972469
Publisher
Nature Publishing Group
Year
2010
Tongue
English
Weight
692 KB
Volume
29
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Inhibition of proliferation and inductio
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (β€˜Iressa’) is independent of EGFR expression level
✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 297 KB πŸ‘ 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant